Andries is the co-founder and serves as Director , a global biotech company builder recognizing the potential of Neuromind Biopharma’s mission to develop novel treatments for depression and PTSD.

Andries is assisting to finance and usher the company to a public listing. Previously Andries was Co-Founder of Biogreen Capital an independent Venture Capital Firm specialising in the Biotech, Healthcare and Natural Medicine Sectors. The company invested into Medical Cannabis start-ups, and structured and completed three additional M&A transactions between Medical Cannabis Companies in 2017, 2018 and 2019.

Andries has also served on the boards for several public and private companies, including holding CF1(Controlling Function) status with the FCA in the U.K.